Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Bone Metastases Clinical Trials

A listing of Bone Metastases medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (23) clinical trials

Study of Patients With Cancer or Precancerous Conditions

OBJECTIVES: - To follow and evaluate patients, longitudinally with cancer or precancerous conditions referred to the NIH Clinical Center Pediatric Oncology Branch who present with disease manifestations that lend themselves to clinical evaluation and are of unique scientific importance. - To allow, when clinically indicated, patients to receive standard care ...

Phase N/A

Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

OBJECTIVES: Primary - Compare the frequency and timing of serious related events (e.g., fractures, radiotherapy to bone, hypercalcemia of malignancy, orthopedic surgery, and spinal cord compression) in patients with advanced breast cancer metastatic to the bone treated with bone marker-directed schedule vs standard schedule zoledronic acid. Secondary - Compare the ...

Phase N/A

Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer

OBJECTIVES: Primary - Measure the efficacy of morphine sulfate at 8 weeks after radiofrequency ablation (RFA) of bone metastases. Secondary - Assess minimum and average pain and analyze use of morphine sulfate before and after RFA. - Determine disease progression by CT scan of bone. - Evaluate the percentage of ...

Phase

Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases

Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose.

Phase N/A

Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223

Every year approximately 12,000 men are diagnosed with prostate cancer in the Netherlands and approximately 2,400 die of this disease. When prostate cancer is limited to the prostate, patients can be operated or radiated with a curative intention, however, metastasized disease is incurable. Initially, prostate cancer responds to testosterone at ...

Phase N/A

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

Serum and blood markers of bone metabolism will be evaluated at Base Line, 1st, 2nd, 3rd and 6th (or last) Radium- 223 treatment. Every blood draw prior to Radium-223 treatment At baseline, tests include (but not restricted to): Testosterone, vitamin D-25-OH (Calciferol), C-reactive protein, Rank Ligand, IL6, BSAF, P1NP and ...

Phase N/A

Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases

This is an single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple subcutaneous injection TK006 in patients with breast cancer-related bone metastases. It contains 4 cohorts:60 mg single-dose conhort, 120 mg single-dose conhort, 180 mg single-dose conhort and 120 mg Q4W (one ...

Phase